Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
09/2003
09/25/2003US20030181437 By reaction of pyrrolobenzothiazepin-9-one with amine to give the corresponding enamine, which is subsequently transformed into the final compound
09/25/2003US20030181420 Modulators of LXR
09/25/2003US20030181415 Use of these compounds for prevention and inhibition of malignant epithelial lesions associated with papilloma virus, such as cervical cancer
09/25/2003US20030181397 Synergistic composition of bioactive fraction isolated barleria prionitis linn and a method of treatment for hepatotoxicity, immuno-deficiency and fatigue and a process thereof
09/25/2003US20030181394 Carbobydrates such as alpha-D-galactopyranosyl-1,2-glycerol and/or isomers, obtained by solvent extraction from algae, for use as viricides or anticarcinogenic agents
09/25/2003US20030181390 Sustained release of aminobutyric acid using prodrugs such as L-1-naphthylalanine-gabapentin, administered for prophylaxis of nervous system disorders, as anxiolytics, antidepressants or antiinflammatory agents; drug delivery
09/25/2003US20030181389 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds
09/25/2003US20030181388 Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire
09/25/2003US20030181362 Receptor
09/25/2003US20030180934 Plasminogen-like polynucleotides, polypeptides, and antibodies
09/25/2003US20030180880 Chromosome 1 gene and gene products related to alzheimer's disease
09/25/2003US20030180877 Gene therapy; drug screening
09/25/2003US20030180805 Methods and compositions for derepression of IAP-inhibited caspase
09/25/2003US20030180785 Polynucleotide molecules encoding Neospora proteins
09/25/2003US20030180753 Full length human hcn1ih channel subunit and variants
09/25/2003US20030180752 Type 2 cytokine receptor and nucleic acids encoding same
09/25/2003US20030180730 Identifying non-sense mutation with codon TGG coding for tryptophan substituted with TAG a non-sense codon at nucleotide 825 in exon 2 of synaptogyrin 1 gene of chromosome 22q11-13, detecting pre-disposition to schizophrenia
09/25/2003US20030180406 Treatment of diseases involving defective gap junctional communication
09/25/2003US20030180402 Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from Acacia
09/25/2003US20030180396 Central nervous system disorders; screening for allergens
09/25/2003US20030180395 Anxiolytic agents; analgesics; sleep disorders; antiinflammatory agents; central nervous system disorders
09/25/2003US20030180394 Extracts from sophora species, method for producing the same and their use
09/25/2003US20030180375 Reduce or prevention brain damage due to neurotransmitters
09/25/2003US20030180360 Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2 (11),3,5,7,9-pentaene
09/25/2003US20030180359 Controlled release
09/25/2003US20030180357 Core with coating; water soluble dye in matrix as core; gellan gum coatings; easier detection of tablet
09/25/2003US20030180332 Novel pharmaceutical composition
09/25/2003US20030180288 Methods and compositions for modulating immune response and for the treatment of inflammatory disease
09/25/2003US20030180269 Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
09/25/2003US20030180253 Stabilized liquid polypeptide-containing pharmaceutical compositions
09/25/2003US20030180249 Storage stability; mixture containing ion exchange resin
09/25/2003US20030180246 Free-flowing anionic surfactant, alkanolamide and electrolytemixture
09/25/2003US20030178295 Via cyanide exchange with cuprous cyanide as solvent; film distillation
09/25/2003CA2488928A1 Method of modulating inflammatory response
09/25/2003CA2479676A1 Dexanabinol and dexanabinol analogs regulate inflammation related genes
09/25/2003CA2479352A1 Carboxylic acid compound and a pharmaceutical agent comprising the compound as an active ingredient
09/25/2003CA2479350A1 Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
09/25/2003CA2479249A1 Neuroprotective spirostenol pharmaceutical compositions
09/25/2003CA2479151A1 Use of proton pump inhibitors for the treatment of noncardiac chest pain
09/25/2003CA2479141A1 Pyridone derivatives
09/25/2003CA2479140A1 Process for preparing crystalline form i of cabergoline
09/25/2003CA2479098A1 Methods and compositions comprising nitric oxide donors and opioid analgesics
09/25/2003CA2479069A1 Hetero-bridge substituted 8-arylquinoline pde4 inhibitors
09/25/2003CA2478997A1 Use of copper chelating tetraamines for the treatment of cardiovascular disease and heart failure
09/25/2003CA2478808A1 Use of asc-1 inhibitors to treat neurological and psychiatric disorders
09/25/2003CA2478805A1 Controlling chemical reactions by spectral chemistry and spectral conditioning
09/25/2003CA2478803A1 Methods of modulating cd200 receptors
09/25/2003CA2478795A1 Use of rapamycin for inhibiting cell death
09/25/2003CA2478790A1 Polypeptides binding to human syntaxin 1a
09/25/2003CA2478758A1 Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo'1,5-bipyridazine in nanoparticulate form
09/25/2003CA2478715A1 Novel pyrazolo [1,5-a]pyridine derivatives and their use as neurotransmitter modulators
09/25/2003CA2478211A1 Nk1 antagonists
09/25/2003CA2477886A1 Preparation of n1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
09/25/2003CA2477832A1 Methods of treating diabetes using pde 11a inhibitors
09/25/2003CA2477732A1 Aminomethyl-substituted thiazolobenzimidazole derivatives
09/25/2003CA2476746A1 Difurylglycolic acid tropenol esters used as anticholinesterase drugs
09/24/2003EP1346992A1 Quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them
09/24/2003EP1346745A1 Apparatus for treatment of tumor in the central nervous system (CNS)
09/24/2003EP1346732A2 Dosage forms for hygroscopic active ingredients
09/24/2003EP1346730A1 Pretargeting methods and novel pretargeting conjugates
09/24/2003EP1346726A1 Sympathetic-activating perfume composition
09/24/2003EP1346226A1 Screening method based on siah-numb interaction
09/24/2003EP1346221A1 A method of assaying for agonists or antagonist of dynorphin a binding to the mas receptor
09/24/2003EP1346056A1 Methods for the production of multimeric proteins, and related compositions
09/24/2003EP1346053A2 Polynucleotides encoding human phosphatases
09/24/2003EP1346042A2 Fat regulated genes, uses thereof, and compounds for modulating same
09/24/2003EP1346041A2 Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
09/24/2003EP1346033A2 Novel serine protease genes related to dppiv
09/24/2003EP1346031A2 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof
09/24/2003EP1345965A2 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
09/24/2003EP1345956A2 Intracellular delivery of biological effectors by novel transporter peptide sequences
09/24/2003EP1345955A2 Lactam dipeptide and its use in inhibiting beta-amyloid peptide release
09/24/2003EP1345947A1 A new process for preparing fused 1,2,4-thiadiazine derivatives
09/24/2003EP1345946A1 Macroheterocylic compounds useful as kinase inhibitors
09/24/2003EP1345942A2 Pyrazinoquinoxaline derivatives as serotonin agonists and antagonists
09/24/2003EP1345941A1 Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors
09/24/2003EP1345938A1 Tricyclic crf receptor antagonists
09/24/2003EP1345936A1 Method for producing the anticholinergic agent tiotropium bromide
09/24/2003EP1345935A2 Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists
09/24/2003EP1345933A2 Process for making substituted 8-arylquinolinium benzenesulfonate
09/24/2003EP1345931A2 Cysteine protease inhibitors
09/24/2003EP1345930A2 Pharmaceutical compounds
09/24/2003EP1345929A2 Pyrazole compounds useful as protein kinase inhibitors
09/24/2003EP1345928A2 Pyrazole compounds useful as protein kinase inhibitors
09/24/2003EP1345927A1 Pyrazole compounds useful as protein kinase inhibitors
09/24/2003EP1345926A2 Pyrazole compounds useful as protein kinase inhibitors
09/24/2003EP1345925A2 Pyrazole compounds useful as protein kinase inhibitors
09/24/2003EP1345922A1 Pyrazole compounds useful as protein kinase inhibitors
09/24/2003EP1345921A1 3-indoline derivatives useful in the treatment of psychiatric and neurologic disorders
09/24/2003EP1345920A1 Novel sulfamides and their use as endothelin receptor antagonists
09/24/2003EP1345914A1 Therapeutic compounds
09/24/2003EP1345909A1 Phenylacetamido-pyrazole derivatives and their use as antitumor agents
09/24/2003EP1345902A1 Substituted heterocyclo-norbornylamine derivatives, method for producing the same, their use as medicament or diagnostic agent and medicament containing the same
09/24/2003EP1345899A1 Compounds
09/24/2003EP1345892A2 Acylaminoalkyl-substituted benzenesulfonamide derivatives
09/24/2003EP1345627A1 Targeted modification of intracellular compounds
09/24/2003EP1345622A2 Eiav chimeric vaccine and diagnostic
09/24/2003EP1345619A2 Use of a composition for the stimulation of nerve growth, the inhibition of scar tissue formation, the reduction of secondary damage and/or the accumulation of macrophages
09/24/2003EP1345616A2 Reducing cellular damage in the human body
09/24/2003EP1345610A1 Method of treatment
1 ... 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 ... 1833